Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies with a collective market capitalization of over $1.7 billion.
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. Rezolute is advancing a diversified pipeline including: RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism; RZ402 (PC), a plasma kallikrein inhibitor targeting Diabetic Macular Edema; and AB101 (Phase 1), a once-weekly injectable basal insulin. For more information, visit: www.rezolutebio.com.
the 2 co. investing 25ml preferred stock purchase in RZLT have a mkt cap of 1.7billion
AntriaBio Inc., ANTB, changed to Rezolute Inc., RZLT:
http://otce.finra.org/DLSymbolNameChanges
$ANTB recent news/filings
bullish
long term bullish divergence
bottoming
## source: finance.yahoo.com
Mon, 29 Jun 2015 13:18:36 GMT ~ ANTRIABIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial St
read full: http://biz.yahoo.com/e/150629/antb8-k.html
*********************************************************
Mon, 29 Jun 2015 12:00:00 GMT ~ AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
[Marketwired] - AntriaBio, Inc. , a biopharmaceutical corporation focused on developing novel extended release therapies, announced today the appointment of David F. Welch, Ph.D., President and Co-Founder of Infinera......
read full: http://finance.yahoo.com/news/antriabio-appoints-david-f-welch-120000659.html
*********************************************************
Mon, 08 Jun 2015 14:47:47 GMT ~ ANTRIABIO, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150608/antb8-k.html
*********************************************************
Mon, 08 Jun 2015 11:30:00 GMT ~ AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
[Marketwired] - AB101 drug substance retained similar receptor binding affinity and receptor-mediated biological activity compared to native insulinSingle dose subcutaneous administration of AB101 in rats and dogs led ...
read full: http://finance.yahoo.com/news/antriabio-announces-promising-preclinical-results-113000567.html
*********************************************************
Wed, 27 May 2015 17:04:09 GMT ~ ANTRIABIO, INC. Financials
read full: http://finance.yahoo.com/q/is?s=antb
*********************************************************
$ANTB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ANTB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ANTB/company-info
Ticker: $ANTB
OTC Market Place: OTCQB
CIK code: 0001509261
Company name: AntriaBio, Inc.
Company website: http://www.antriabio.com
Incorporated In: DE, USA
Business Description: AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection.
$ANTB share structure
## source: otcmarkets.com
Market Value: $46,242,616 a/o Jul 17, 2015
Shares Outstanding: 24,338,219 a/o Jun 25, 2015
Float: 21,533,279 a/o Jun 25, 2015
Authorized Shares: 200,000,000 a/o Jun 25, 2015
Par Value: 0.001
$ANTB extra dd links
Company name: AntriaBio, Inc.
Company website: http://www.antriabio.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ANTB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ANTB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ANTB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/news - http://finance.yahoo.com/q/h?s=ANTB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ANTB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ANTB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ANTB
DTCC (dtcc.com): http://search2.dtcc.com/?q=AntriaBio%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=AntriaBio%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=AntriaBio%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.antriabio.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.antriabio.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.antriabio.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ANTB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001509261&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ANTB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ANTB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ANTB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ANTB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ANTB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ANTB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ANTB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ANTB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ANTB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ANTB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ANTB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ANTB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ANTB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ANTB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ANTB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ANTB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ANTB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ANTB
$ANTB DD Notes ~ http://www.ddnotesmaker.com/ANTB
$ANTB...Annouunces Appointment Of Dr. Hoyoung Huh As Chairman Of Scientific Advisory Board And Business Development
inShare
1/9/2015 9:08:22 AM
LOUISVILLE, CO and MENLO PARK, CA--(Marketwired - January 08, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board.
Dr. Huh stated, "AntriaBio has tremendous potential to transform the therapeutic regimen in diabetes and significantly improve the standard of care in other disease states. The Company has matured and achieved critical milestones over the past 12 months, including compelling preclinical studies in multiple animal species for its lead product candidate, AB101."
In his expanded role, Dr. Huh will partner with his long-time colleague, Nevan Elam, the Company's Chairman and Chief Executive Officer, as well as the Chief Scientific Officer, Dr. Sankaram Mantripragada.
"We are very excited to have Hoyoung join us in a more direct capacity as we seek to broaden AntriaBio's vision and strategy. Hoyoung is a widely respected visionary and entrepreneur in our industry. His insights and direction will be invaluable as we head into the next phase of our growth," noted Mr. Elam.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $10 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit: www.antriabio.com.
http://www.biospace.com/news_story.aspx?StoryID=360597&full=1
Colorado Roundup: AntriaBio Raises $7M,
Michael Davidson1/9/15Follow @MichaelXBD
A biotech startup chases the $10 billion market for diabetes treatments, and Artifact Uprising is snapped up by another photography startup.
AntriaBio raises $7 million, clears hurdle. Biopharmaceutical company AntriaBio announced this week it has raised about $7 million in a private placement. The company develops extended release therapies, and currently is at work on a form of insulin that people with type 1 and type 2 diabetes could inject once a week.
AntriaBio believes the addressable market for its diabetes drug could be as high as $10 billion.
That drug, AB101, is going through pre-clinical trials in animals. AntriaBio also announced this week it had passed a series of in vitro and multi-species animal studies testing the “receptor pharmacology, pharmacokinetics, and pharmacodynamics” of the drug. The company is conducting toxicology studies that would be the next step before clinical studies in patients with type 1 diabetes. AntriaBio would like to start that trial this year.
The new investment will be used to fund the initiation of phase 1 clinical studies, a press release said. AntriaBio raised more then $18 million through equity financings in 2014, the company also said.
AntriaBio conducts its research, development, and manufacturing in Louisville, which is outside Boulder. The company is headquartered in Menlo Park, CA, but everyone except its CEO works out of Louisville.
Jason Napodano, CFA ?@JNapodano 4h4 hours ago
Early-stage diabetes company $ANTB raised $7M through a PIPE at $1.85 this morning. Stock is $1.28. Interesting they got funds to over pay.
$ANTB...ANTRIABIO ANNOUNCES $7 MILLION PRIVATE PLACEMENT
Download PDF
LOUISVILLE, CO -- (Marketwired) -- 01/05/15 -- AntriaBio, Inc. ("Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7 million in a private placement transaction. At $1.85 per unit, institutions and accredited investors were issued one share of common stock and one warrant exercisable for three years at $2.50 for one share of common stock. Notably, the Company was successful in raising over $18 million through equity financings in 2014.
AntriaBio will use the proceeds from its most recent financing for general corporate purposes including the production of cGMP material and initiation of Phase 1 clinical studies for AB101, a basal insulin with potential for once-weekly dosing for patients with type 1 and type 2 diabetes.
Nevan Elam, Chairman and Chief Executive Officer stated, "Our fundraising efforts in 2014 were instrumental in advancing our clinical program for AB101. The confidence that our investors have shown in us is a testament to our extended release platform and the potential of AB101 to transform the $10 billion basal insulin market."
The securities sold in the financing have not been registered under the United States Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the US absent registration or an applicable exemption from registration requirements. As part of the financing, the Company has agreed to file a resale registration statement on Form S-1 with the United States Securities and Exchange Commission within 90 days of the closing of the financing for purposes of registering the resale of the shares of common stock issued or issuable in connection with the financing.
This press release is being issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. For more information visit: www.antriabio.com.
http://www.antriabio.com/news/press-releases/detail/204/antriabio-announces-7-million-private-placement
WTF, a new article comes out today and it tanks 33% right at the end of the day? Smells like a pump and dump.
Is once weekly injection the future to diabetic therapy?
AntriaBio is taking a different approach to their treatment from other basal insulin therapies. Though still in preclinical trials, this is a hot topic with MannKind's approval. Prior early stage diabetes deals are in the hundreds of millions, offering huge upside for ANTB.
http://lastfinancier.com/antriabio-vast-upside-disruptive-once-weekly-insulin/
I've just received my 2nd invite from this company via the mail, inviting me to their presentation in Dallas. Never even heard of this company until I received my first invite.
Has anyone else received these mailers?
ANTB one for 6 reverse split:
http://www.otcbb.com/asp/dailylist_detail.asp?d=04/30/2014&mkt_ctg=NON-OTCBB
ANTB NEWS!
AntriaBio Announces Closing of Bridge Financing Company Prepares to Advance Innovative Lead Product Candidate, AB101, for the Treatment of Diabetes Into Clinical Development
MENLO PARK, CA--(Marketwired - Jan 16, 2014) - AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that it has closed a $2.7 million bridge note financing (the "Bridge Financing") in an exempt private placement transaction with a number of accredited investors. Paulson Investment Company, Inc. served as the Company's sole placement agent in the transaction.
The Company plans on raising additional funds in a private placement transaction in the first quarter of 2014 as it prepares for clinical studies for its lead product candidate, AB101, a proprietary, microsphere formulation of insulin that has the potential to be administered once per week and transform the treatment paradigm in the more than $8 billion a year basal insulin market.
Nevan Elam, AntriaBio's Chairman and CEO stated, "Securing sufficient funding this quarter is critical to advance our clinical development plans for AB101 and this Bridge Financing is the first step in our funding strategy."
The Bridge Financing will be used for general corporate purposes including the establishment of a cGMP manufacturing facility in the greater Denver, Colorado area. Pursuant to the terms of the Bridge Financing, the Company issued 8% unsecured convertible promissory notes with warrants to purchase shares of common stock at an exercise price of $0.315. The warrants issued in connection with the Bridge Financing will expire three (3) years from their issue date. AntriaBio received net cash proceeds of $2.7 million in the Bridge Financing, excluding placement agent compensation, transaction costs, fees and expenses in the Bridge Financing.
Additional details about the offering will be filed today on AntriaBio's Form 8-K with the Securities and Exchange Commission and available under "Investor Relations - SEC Filings" at www.antriabio.com.
The unsecured convertible promissory notes, the warrants, and any other securities offered in the Bridge Financing or any other securities to be offered in any proposed future private placement (collectively, the "Securities") have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction. Because the Securities are not registered, the Securities may not be offered or sold in the United States absent registration or an exemption from registration. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of the securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Contact:
AntriaBio, Inc.
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
(908) 938-1475
ANTB 10Q filed
AntriaBio, Inc. has filed the following documents with the SEC:
SEC Filing Alert
10-Q: Quarterly report pursuant to sections 13 or 15(d)
HTML PDF
If you have any questions, or would like to contact Investor Relations, please reply to this email.
AntriaBio, Inc. | 890 Santa Cruz Avenue | Menlo Park, CA 94025
http://www.antriabio.com
ANTB News!!
AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
MENLO PARK, CA--(Marketwired - Jul 24, 2013) - AntriaBio, Inc. (OTCQB: ANTB) announced today that it has received an allowance from the European Patent Office for Patent Application No. 04759347.0 entitled "Method for Preparation of Site-Specific Protein Conjugates" with claims directed to the Company's lead diabetes product candidate, AB101. This patent was also allowed in Australia.
AB101 is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.
The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. AB101's long duration of action is the result of AntriaBio's ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA-approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com
Safe Harbor
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.
Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Contact:
Jamie Spring
AntriaBio, Inc.
999 18th Street
Suite 3000
Denver, CO 80202
Phone: 303-357-4651
Fax: 303-446-9111
jspring@antriabio.com
Appears it never left the gate
Looks like it wasn't an opportunity at all?
Seemingly endless supply of shares for sale here. Smelling rotten in ANTB.
looks like a big pump and dump.
broke a dollar, something is up!
This pullback keeps growing?
AntriaBio Pullback Could Spell Opportunity
AntriaBio, Inc. (ANTB.OB) is another still-developing player in the sector of diabetes treatment that has recently pulled back and could be worth a look to both short- and long-term investors. This company is bringing to human trials over the near term a once-a-week basal insulin shot (AB101) that would look to replace the once-daily current standard of care. The noted benefits to a patient's quality of life that this product could have to those currently needing a shot a day is obvious, and AntriaBio shares have the potential to move in-line with catalysts as they develop during the coming quarters - especially in light of the recent pullback. After hitting highs of over two roughly a month ago, the share price has trickled lower on light volume, an indication that those who are already in are holding, while others looking to get in may do so when the see the share price settle. Given the relatively light volume, however, this one could still be trading below the radar - but that could change as progress is made this year in the clinical development of AB101.
Human trials in Russia are slated to begin over the near term and once data starts rolling in from those trials, then AntriaBio plans to use that data - assuming its positive - to search for potential partners, whether they be regional or international, according to a recent presentation (pdf). Diabetes is growing at a very rapid pace worldwide, as discussed in the SanuWave write-up, so AntriaBio could be positioning to enter a very lucrative market and could attract the swift interest of partners or potential acquirers if human trials move forward with success.
In addition to the above-mentioned catalyst events, FDA milestones could be forthcoming, as well, as the company has stated plans to proceed with the IND process in the U.S. while simultaneously conducting trials overseas. Emphasis has been put on the overseas trials first, however, due to significant costs benefits of conducting trials elsewhere, while patient recruitment is often easier, too. Once some human data is established, then it makes the FDA process at home a little bit easier. The path to approval should also be estimated as quicker than the standard drug approval process, due to the established nature of basal insulin, meaning developments could unfold quickly once trials are started.
Standard risks apply for developmental companies in the sector, but the recent price pullback, pending catalysts and overall potential of AB101 in the commercial market - should it make it that far - makes AntriaBio's recent trading action worth watching.
http://seekingalpha.com/article/1298501-weekly-stock-watch-week-of-march-25?source=yahoo
Interesting Info ... Hope they all read it
http://biotechintel.com/blog/2013/3/12/antria-bio-antb
Novo Nordisk - the world's largest insulin producer - and major diabetes drug manufacturers - could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment.
Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi's $6 BILLION-A-YEAR basal insulin - 'Lantus' - OBSOLETE.
The Company that's making executives in the world's largest pharmaceutical firms sweat is Menlo Park, California-based ANTRIABIO, INC. (ANTB)
Here's why large pharma is worried about ANTRIABIO's technology:
1. Basal insulin is prescribed as a once-daily injection; Antriabio is developing a once-weekly version.
2. Big Pharma long-ago realized the need for longer-acting insulin - but the best they've been able to produce is a thrice-weekly (3X per week) regimen.
3. But even the thrice-weekly regimen, developed by Novo Nordisk, was recently rejected by the FDA for marketing in the United States - the world's most lucrative diabetes market.
4. The FDA has made it clear that it will not compromise patient safety for Novo Nordisk's 'longer-acting' insulin drug.
5. Analysts estimate the FDA setback will cost Novo Nordisk BILLIONS and delay launch to 2018 or later, and perhaps indefinitely, because their drug has been linked to heart complications.
6. Antriabio's long-acting basal insulin is developed using a well-validated (PROVEN) and widely-accepted (SAFE) technology call PEGYlation. The company patented use of this technology with insulin, which makes virtually every competitor in diabetes OBSOLETE.
7. Market Research suggests that by 2018, sales of insulin will reach $32 BILLION globally, and every pharmaceutical company seeing revenue dry up because of expiring patents will want a piece of this ENORMOUS market.
8. In 2012, patent expiration cost pharmaceutical companies more than $34 BILLION in sales; the loss will balloon to $147 BILLION by 2015.
9. If global pharmaceuticals companies want to remain competitive, they'll need to find disruptive technologies with extensive patent life targeting large markets, and partner with or outright acquire such technologies. In other words, big pharma is seeking technologies like Antriabio's long-acting basal insulin - which to them is worth BILLIONS OF DOLLARS.
Big pharma is sitting on the largest stockpile of cash seen in history - cash that was accumulated selling lucrative drugs that will now go off-patent and cause losses to the tune of $147 BILLION in 2015 alone.
However, big pharma isn't sitting idle. Furthermore, executives at the world's largest pharmaceutical companies recognize their livelihood is at stake.
Big Pharma has progressively been acquiring disruptive technologies with long patent life targeting large markets like diabetes.
Last year, Bristol Myers Squibb spent $7 BILLION to acquire Amylin and their portfolio of GLP-1, a type of insulin prescribed to patients to help treat type-2 diabetes.
The acquisition of Amylin sparked a BIDDING WAR among:
1. AstraZeneca (AZN),
2. Pfizer (PFE)
3. Merck (MRK)
4. Sanofi Aventus (SNY)
5. Bristol Meyers Squibb (BMS)
This clearly proves that big pharma is not only interested but DESPERATE for products that will help them remain competitive.
What's incredible is that Antriabio has an even better version of Amylin's once-weekly GLP-1 drug - a super-long acting, once-monthly treatment.
To recap:
Novo Nordisk + Sanofi saw sales north of $8 BILLION just on their daily basil insulin product
Antriabio is developing a once-weekly version - called AB101 - that promises to make these existing products OBSOLETE
Bristol Myers Squibb paid $7 BILLION for Amylin's once-weekly GLP-1 insulin drug in 2012
Antriabio is developing a once-MONTHLY version of the GLP-1 drug - called AB201 - that sees annual sales of >$1 Billion.
We believe Antriabio will trade upwards as Big pharma continues to see their patents expire and suffer billions of dollars in recurring sales losses, Drug makers struggle to create SAFE, long-acting insulin products, Antriabio advances its technology and
Big pharma eventually bids to acquire Antriabio to eliminate the threat this small company poses and equally to secure a future worth BILLIONS to the big pharma companies who have established sales channels and distribution in diabetes care.
We like Antriabio as a company that is undiscovered by investors, boasts excellent management with a track record of success in biotech, and has strong intellectual property (IP) and patent life.
Last year, we saw Organovo, the world's first 3D Bio-Printing company quietly emerge as a public company. It debuted at $1.65 and rally to $11, before settling mid-range. Organovo successfully raised more than $25MM and is now weeks away from listing on a national exchange, likely the NASDAQ. Moreover, it is one of the most active issues traded over-the-counter. Organovo, like Antriabio, was once completely unknown to investors, but later emerged as one of the best-performing equities of 2012.
Organovo's disruptive technology in cell-based research suggests Antriabio should perform on par, if not better, during the course of this year, and beyond.
We anticipate Antriabio will be one of the best performing equities in 2013, supported by fundamentals that will eventually drive a large pharmaceutical company to acquire them at a huge premium to their current price. For some more information on Antriabio, view their overview.
?
..AntriaBio Set for a Major Short Squeeze
......LOS ANGELES, CA--(Marketwire - Mar 14, 2013) - A handful of early investors are fighting an uphill battle after investing in shares of AntriaBio ( OTCBB : ANTB ), which recently swooped in to snag an intriguing lead diabetes product, AB101, after a private firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.
According to short interest data on octshortreport.com, approximately 50% of AntriaBio shares trading hands since February 11, 2013 were sold 'short' (as shown below).
Historical Short Selling Data
Date VolShorted
12-Mar 68.09%
11-Mar 68.09%
8-Mar 46.81%
7-Mar 45.52%
6-Mar 20.00%
5-Mar 38.81%
4-Mar 58.15%
1-Mar 37.91%
28-Feb 32.10%
27-Feb 0%
26-Feb 25.91%
25-Feb 63.67%
22-Feb 70.12%
21-Feb 95.41%
20-Feb 64.13%
19-Feb 43.68%
15-Feb 0%
14-Feb 0%
13-Feb 0%
12-Feb 32.89%
11-Feb 5.00%
Source: otcshortreport.com
AntriaBio -- which went public in January of this year -- is developing a novel, once-weekly version of a basil insulin product that saw sales well over $8 Billion last year. Sanofi's 'Lantus', a once-daily basil insulin prescribed to help control blood sugar levels in diabetics, is expected to boost its take to $6.6B in 2013. Drug makers stand to make billions capitalizing on a disease that's estimated to affect as many as 30 million people in the United States alone. The American Diabetes Association (ADA) reported this year that the cost of diabetes in the U.S. has swelled to $245 Billion, up from $132 Billion a decade ago. As the table (below) shows, diabetes has long-ago surpassed 'cumbersome', made a left at 'concerning' and sits dead-center at 'epidemic'.
YEAR National cost of diabetes (inflation adjusted) Growth from five years prior (inflation-adjusted)
2012 $245 billion 41% (21%)*
2007 $174 billion ($202 billion)* 32% (15%)**
2002 $132 billion ($168 billion)** 35% (20%)**
1997 $98 billion ($140 billion)** -
*As Provided by the ADA
** Using the Bureau of Labor Statistics' CPI Inflation Calculator
Source: Close Concerns
Diabetes therapy and technology accounted for only 12% of the $176 billion in direct medical costs attributed to diabetes in 2012; hospital inpatient care accounted for 43% of costs, a breakdown by the ADA shows. Close Concerns, a leading independent diabetes research firm, concluded on the basis of this data:
"We believe that policies aimed at preventing type 2 diabetes and their complications and on optimizing diabetes management for patients could ultimately produce better cost savings than policies aimed at limiting treatments [...] Additionally, preventing type 2 diabetes and its associated complications would greatly reduce the indirect costs of diabetes -- something reducing access or prices will not accomplish."
This suggests that investors who have sold short shares of Antriabio could soon find themselves at odds with a bourgeoning global market demanding better drugs for "optimized diabetes management". AB101, AntriaBio's basil insulin drug candidate, is a once-weekly anologue that would compete with approved therapies taken once-daily. As the company gains visibility, short sellers could be "squeezed" betting against an emerging technology targeting several established (and growing) multi-billion dollar drug franchises with a superior, longer-acting analogue.
As we've observed with other emerging biotechnology companies such as Sarepta (SRPT), Opko Health (OPK), and Santarus (SNTS) (and countless other cases), catalysts like scientific presentations, strategic collaborations, peer-reviewed study publications, and positive data releases have literally added hundreds of millions of dollars to these names overnight. In the context of publicly-traded companies, this means a sharp re-valuation of shares spurred further on by short sellers scrambling to cover their "borrowed" positions.
Sarepta, for instance, saw more than 12% of its float "sold short" by mid-August while climbing from $8 to $16-a-share over the next 6 weeks.
But in mid-October, data on a small study of 12 patients given eteplirsen, the company's experimental drug for muscular dystrophy, sent shares of the biotech company soaring to $31.80 overnight, closing at $45 the same day.
Similarly, since mid-December, Opko Health (OPK), led by Billionaire healthcare entrepreneur Phil Frost, catapulted over 65% as the company acquired several strategic late-stage assets, completed an oversubscribed $175 Million notes offering and saw a flurry of insider buying. At the beginning of December, 1 in 5 shares "floating" was sold short in Opko Health. According to NASDAQ.com, short interest declined roughly 24%, by mid-January, suggesting short sellers were being squeezed and possibly contributing to the rally in share price.
As AntriaBio gains visibility amongst risk-tolerant investors, short sellers could once again finds themselves scrambling to cover their [short] positions. In particular, short sellers may not:
1. Understand the scope of the company and/or their product offering,
2. Comprehend the growing market need and opportunity for a longer-acting insulin drug(s), or
3. Have the foresight to assess the impact that one or several catalysts could have on the price of Antriabio stock in 2013.
Among other catalysts that could ignite shares of this emerging diabetes-drug maker, presentations at scientific meetings, peer-reviewed publications, and initiation of a human clinical study in the second quarter of this year, AntriBio could become the focus of M&A activity, as titans like Novo Nordisk (NVO) see the FDA reprimand and reject a thrice-weekly basil insulin over safety concerns. Investors may recall that a bidding war erupted over Amylin last year, culminating in a $7 Billion+ takeover by Bristol Myers Squibb (BMS).
Amylin's long-acting GLP-1 product(s), a market notably smaller than basil insulins, had sparked the takeover frenzy.
The full version of this report complete with charts and disclosures can be found at: http://www.biomedreports.com/20130314127114/antriabio-set-for-major-short-squeeze.html
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
..Contact:.
.Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
.
...
boom has been postponed... not for awhile...
congrats who was able to join/add today... expect to see a lot of activities tomorrow...
pps reflects the effect of BioMedReports. lol
Hopefully not for long...
Once-a-Week Insulin Shot Could Help Growing Diabetes Patient Base and Spell Huge Profits for Investors Marketwire "Press Releases"
LOS ANGELES, CA -- (Marketwire) -- 02/22/13 -- In January 2013 , newly trading AntriaBio, Inc. (OTCQB: ANTB) acquired one of the most-interesting and buzzworthy assets we've seen in some time from a private company called PR Pharmaceuticals .
AntriaBio swooped in to snag the intriguing lead diabetes product, AB101, after that firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.
The team at AntriaBio was getting a great deal of attention at the recent Healthcare Conferences in San Francisco -- well before the company was even publicly trading as it is now. Why? Not only because the lead product had already seen substantial private capital development investment, but also because AB101 offers potential significant advantages over basal insulin products offered by Sanofi-Aventis and Novo Nordisk; whose products Lantus and Levemir have a combined $8B in annual sales.
From an investment standpoint, we like AntriaBio because the value for the lead product is clearly established but has not yet been recognized by the public markets. As their story begins to spread and more analysts begin to recognize its value, the stock price of this very-low-float company should begin to increase.
Looking at the situation from an industry standpoint, we have seen dozens of stories and several examples of industry titans buying once discarded unique assets with substantial market potential, for big money. See Amgen's acquisition of deCODE Genetics for $415MM in December 2012 as one.
"The company (deCODE) declared bankruptcy in 2009 and was rescued by some of its original investors, who acquired the firm and its assets for around $14 million and went on to invest another roughly $45 million ."
Literally weeks ago Baxter /Cangene stepped up to acquire an investigational hemophilia compound and other assets from the bankrupted Inspiration BioPharmaceuticals.
These biotechnologies were bought for pennies on the dollar and once their true value came to be recognized the acquisitions led to substantial profits.
The same should hold true for AntriaBio -- especially given that the incidence of diabetes is increasing rapidly and that this one-a-week insulin replacement therapy could be very appealing to individuals with diabetes who need to mimic healthy pancreas function by delivering insulin consistently day and night (basal insulin) and as needed following meals (bolus insulin).
In fact, if approved, AntriaBio believes AB101 will result in greater patient compliance (once weekly delivery versus once daily). Keep in mind, also, that the number of just over 300 million individuals with diabetes is expected to grow to be 550 million by 2030.
AntriaBio proposes that AB101 would be administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level that supplements the effects of bolus insulin and complements the effects of other diabetes medications.
The firm has a very smart and efficient clinical approval pathway that includes for the possibility that AB101 may be able to be marketed in Russia while US and EU studies move forward at a slower pace.
This is a fascinating and innovative technology led by a group with plenty of product experience and we will follow this story as it unfolds.
In the meantime, given the share-count actually in the float currently, it may be wise for both traders and long-term holders to consider establishing positions in front of upcoming catalysts and before this marked biotech's popularity begins to spread.
Disclosure: Author M.E. Garza is Long ANTB
The full version of this report complete with presentation slide deck images chart can be found here:
http://www.biomedreports.com/20130222124061/once-a-week-insulin-shot-could-help-growing-diabetes-patient-base-and-spell-big-profits-for-investors.html
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only: M. Davila Assistant Editor BioMedReports.Com e-mail: Email Contact
http://www.linkedin.com/jobs/jobs-Scientist-Analytical-Development-4821796
Scientist, Analytical Development - 2 Positions Available
AntriaBio, Inc. - Front Range (Greater Denver Area)
Job Description
This position is located in the vicinity of Denver, Colorado. As a member of the Research and Development group, works with AntriaBio team members in developing and validating analytical methods for sustained release formulations. Possesses a high level of expertise with proteins, peptides and biodegradable polymers. Experienced in using analytical methods in the general chapters and monographs in the USP/NF and Pharm. Eur. Experienced in ICH guidelines. Experienced in meeting corporate objectives. The specific job title will depend on the education, skills and experience of the candidate.
Desired Skills & Experience
- PhD strongly preferred. BS and MS candidates with relevant experience are encouraged to apply.
- Experience within pharmaceutical (bio) analytical methods development and validation.
- Experience in Quality Control and compliance with GLP.
- Experience with the use of separation chemistry based methods development and validation.
- Experience in writing CM&C sections for regulatory submissions.
- Experience in small to mid-size companies
- Superior interpersonal skills required. Must be able to establish peer relationships and communicate effectively with company disciplines, cross-functional, and external teams
- Experience in managing/leading cross-functional teams
- Proven ability to simultaneously manage activities associated with multiple projects and programs with short timelines.
- Attention to detail and commitment to high quality and on-time deliverables is required.
- Expert computer skills required.
- Proven ability to successfully manage people in matrix setting.
chart has been updated in the IBox
From: StockCharts.com Support
Sent: February 20, 2013 8:44 AM
To: ***@***.com
Subject: Your Symbol Request Was Processed (StockCharts.com)
Thank you for your recent symbol request.
Based on your suggestion, we have added [ANTB] to our charting database:
stockcharts.com/h-sc/ui?s=antb
Thanks for using StockCharts.com,
StockCharts Support
support@stockcharts.com
http://stockcharts.com
AntriaBio Appoints Two Industry Leaders to Its Management Team
MENLO PARK, CA -- (Marketwire) -- 02/19/13 -- AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013 , of two new members to its management team: Nevan Elam , as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada , Ph.D., as AntriaBio's Chief Scientific Officer.
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited , a medical device company based in Europe . Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia , Latin America and the Middle East . Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University .
Sankaram Mantripragada , Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009 , Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013 , AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe , Executive Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than eight patents.
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation , now part of Abbott Vascular . Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine . Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany .
tomorrow could be last chance to enter at these bottom prices
found some good summaries here: http://pennystockhaven.com/mid-term-investment-opportunity-with-antriabio-fmyyd/
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
392
|
Created
|
01/20/13
|
Type
|
Free
|
Moderators |
"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |